TriSalus Life Sciences, Inc.
No enriched coverage for $TLSI in the last 7 days.
Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.
Worthington Enterprises (NYSE:WOR) shares rose 15.9% in pre-market trading after reporting Q1 earnings of $0.82 per share, beating estimates of $0.75, and sales of $343.89M, exceeding expectations of $331.27M.
KB Home (KBH) rose 2% post-market on strong sector signals. Worthington Enterprises (WOR) surged 14% after Q1 earnings beat estimates. IonQ (IONQ) climbed 8% on quantum error correction milestone. TriSalus Life Sciences (TLSI) jumped 28% after FDA clearance. InnovAge (INNV) dropped 12% on secondary stock offering.
Recent TLSI coverage spans financial news, regulation and earnings.
In the last 30 days, TLSI insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($4K). The most active reporter was Cox Bryan F., Chief of Research, with 1 filing.
Device clearance broadens its interventional portfolio.
Regulatory clearance supports price rise.
Regulatory clearance unlocks new product revenue.
The FDA clearance expands TriSalus' product portfolio and enables market release, likely supporting near-term revenue growth.
The clearance enables market release of a new device, likely boosting revenue prospects and stock momentum.
AlphAI scores every news story that mentions TLSI with an AI model for sentiment and relevance, and aggregates insider trades from TriSalus Life Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.
3 min readWorthington Enterprises (NYSE:WOR) shares rose 15.9% in pre-market trading after reporting Q1 earnings of $0.82 per share, beating estimates of $0.75, and sales of $343.89M, exceeding expectations of $331.27M.
2 min readKB Home (KBH) rose 2% post-market on strong sector signals. Worthington Enterprises (WOR) surged 14% after Q1 earnings beat estimates. IonQ (IONQ) climbed 8% on quantum error correction milestone. TriSalus Life Sciences (TLSI) jumped 28% after FDA clearance. InnovAge (INNV) dropped 12% on secondary stock offering.
2 min readTriSalus Life Sciences (TLSI) shares rose 29% after receiving FDA 510(k) clearance for TriNav Advance, a new device for its Pressure-Enabled Drug Delivery portfolio. The device expands access to small, distal vessels and supports a broader range of embolization procedures. The company plans a limited market release soon. According to the company, the device enhances its portfolio and enables physicians to optimize therapeutic delivery in complex cases.
2 min readTriSalus Life Sciences, Inc. (TLSI) filed an SEC Form 8-K — Other Events. TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery TM (PEDD TM ) Portfolio for Liver Embolization WESTMINSTER, Colo. – September 22, 2026 – TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an o
2 min readAnalysts initiated coverage on several companies: StoneX started HOOD with a Buy and $170 target, HC Wainwright began TLSI with a Buy and $11 target, Needham initiated KDK with a Buy and $8 target, BMO rated DECK Underperform with a $70 target, and Cantor Fitzgerald gave SGMT an Overweight rating.
1 min readTriSalus Life Sciences, Inc. (TLSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. TriSalus Life Sciences Reports Second Quarter 2026 Results Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration Maintains 2026 revenue guidance of $54 million to $57 million Hosting Conferen
6 min readTriSalus Life Sciences (TLSI) will present new clinical and preclinical data at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The presentations will highlight the capabilities of its Pressure Enabled Drug Delivery (PEDD) platform for applications in liver-directed therapies and uterine artery embolization, demonstrating the platform's versatility in enhancing therapeutic delivery across various disease states. The company's CEO, Mary Szela, and CMO, Richard Marshall, emphasized the growing body of evidence supporting PEDD's potential to improve patient outcomes by enabling more effective delivery of therapies.
3 min readThis article provides a detailed financial overview of TriSalus Life Sciences, Inc. (TLSI), including its stock price performance, key financial metrics, upcoming earnings, and analyst ratings. It describes the company's business in oncology, focusing on its integration of treatments for liver and pancreatic tumors, and offers answers to frequently asked questions about its stock and financial health.
4 min readImage source: The Motley Fool.Thursday, November 13, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min read
